Jump to content
alanbarlee

Apalutamide - 2 Phase 3 clinical trials

Recommended Posts

alanbarlee

Apalutamide (JNJ-56021927 formerly known as ARN 509) is a novel small-molecule androgen receptor antagonist similar to enzalutamide but with less central nervous system penetration, which could potentially result in reduced levels of fatigue and seizures.

Curetoday.com has an article about 2 Phase 3 clinical trials of Apalutamide:

The SPARTAN study is currently recruiting in Australia; the ATLAS study is not.

For SPARTAN, eligible patients must show no signs of evident metastatic prostate cancer and must have a high risk for disease progression.  A high risk for disease progression is defined as either a PSA doubling time (PSADT) of less than 10 months while on continuous ADT, or Castrate Resistant Prostate cancer demonstrated while on continuous ADT.   PSADT is calculated using at least three PSA values during ADT.

 

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...